H1N1 Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The H1N1 Vaccines market is segmented By Product Type (Inactivated Vaccine, Live Attenuated Vaccine), By Route of Administration and Geography.

Home Market Analysis Healthcare Research Pharmaceuticals Research Finished Dosage Form Research Vaccines Research H1N1 Vaccines Market

H1N1 Vaccines Market Size

H1N1 Vaccines Market CAGR
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.20 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

H1N1 Vaccines Market

*Disclaimer: Major Players sorted in no particular order
setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

H1N1 Vaccines Market Analysis

The H1N1 Vaccines Market is expected to register a CAGR of 5.2% during the forecast period. The H1N1 virus, commonly known as swine flu is an infectious disease in humans caused by the swine H1N1 virus, which is characterized by a persistent cough, cold, high fever, red watery eyes, body aches, headache, and general discomfort. H1N1 virus affects various species such as swine, birds, horses and other animals. The H1N1 virus is contagious and can spread widely through small droplets of saliva from coughs or sneezes of infected person. H1N1 virus causes damage to the respiratory system including nose, lungs, and throat. The H1N1 virus is a Ribonucleic acid (RNA) virus belonging to the Orthomyxoviridae family. In the year 2009, a strain of swine flu called "H1N1" infected many people around the world.

According to the World Health Organization (WHO), annually about 3 to 5 million cases of severe illness and about 2,90,000 to 6,50,000 respiratory deaths are due to seasonal influenza. In the case of industrialized countries, most of the deaths due to influenza occur among people above 65 years of age. Seasonal influenza illnesses range from mild to severe and even death.

Increasing incidences of epidemic H1N1 infection and declining immunity among the geriatric population and technological advancements in the vaccines are the key driving factors in the H1N1 vaccines market.

H1N1 Vaccines Market Trends

This section covers the major market trends shaping the H1N1 Vaccines Market according to our research experts:

Intramuscular Vaccines Segment is Expected to Witness a Rapid Growth

An intramuscular injection is a procedure used to deliver a medication deep into the muscles which allows the medication to be absorbed into the bloodstream quickly. Intramuscular injections are absorbed faster than subcutaneous injections because muscles have a greater blood supply than the tissue present under the skin. Moreover, muscle tissue can also hold a larger volume of medication than subcutaneous tissue. According to the 2017 United Nations report, the global population is crossing the age of 60 at an annual rate of 3% which maximizes the risk of various diseases such as respiratory tract disorders and immune deficient diseases, thereby the risk for infection due to H1N1 virus rises.

The intramuscular vaccines segment holds a significant market share in the H1N1 vaccines market and is anticipated to show a similar trend over the forecast period. Rising incidences of swine flu and the need for H1N1 vaccination is increasing and  increased risk of respiratory diseases and immune-deficient diseases among the geriatric population are the key driving factors in the intramuscular vaccines segment.

H1N1 Vaccines Market key trend 1

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the H1N1 vaccines market due to increasing government initiatives for the prevention of H1N1 infection and improved research infrastructure in this region. According to the Centers for Disease Control (CDC), about 8 percent of the United States population gets sick from the flu. In addition, approximately 31.4 million people visit the doctor and 200,000 people end up in the hospital every flu season. Moreover, technological advancements in the vaccines field and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

H1N1 Vaccines Market 2

H1N1 Vaccines Industry Overview

The H1N1 Vaccines Market is consolidated and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are MedImmune LLC (AstraZeneca PLC), Sanofi Pasteur AG, GlaxoSmithKline Plc, Abbott Laboratories, CSL Limited (Seqirus GmbH), Pfizer Inc, CPL Biologicals Pvt. Ltd, Mitsubishi Tanabe Pharma Corporation, Sinovac Biotech Ltd and Zydus Cadila.

H1N1 Vaccines Market Leaders

  1. AstraZeneca Plc

  2. Sanofi (Sanofi Pasteur AG)

  3. GlaxoSmithKline Plc

  4. Abbott Laboratories

  5. CSL Limited (Seqirus GmbH)

*Disclaimer: Major Players sorted in no particular order

H1N1 Vaccines Market landscape
Need More Details on Market Players and Competitors?
Download Sample

H1N1 Vaccines Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidences of Epidemic H1N1 Infection and Declining Immunity Among people

      2. 4.2.2 Technological Advancements in the Vaccines Field

    3. 4.3 Market Restraints

      1. 4.3.1 High costs of H1N1 Vaacines

      2. 4.3.2 Lengthy Manufacturing Process of H1N1 Vaacines

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Inactivated Vaccine

      2. 5.1.2 Live Attenuated Vaccine

    2. 5.2 By Route of Administration

      1. 5.2.1 Intradermal Vaccines

      2. 5.2.2 Intramuscular Vaccines

      3. 5.2.3 Intranasal Vaccines

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 MedImmune LLC (AstraZeneca PLC)

      2. 6.1.2 Sanofi Pasteur AG

      3. 6.1.3 GlaxoSmithKline Plc

      4. 6.1.4 Abbott Laboratories

      5. 6.1.5 CSL Limited (Seqirus GmbH)

      6. 6.1.6 Pfizer Inc

      7. 6.1.7 CPL Biologicals Pvt. Ltd

      8. 6.1.8 Mitsubishi Tanabe Pharma Corporation

      9. 6.1.9 Sinovac Biotech Ltd

      10. 6.1.10 Zydus Cadila

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

H1N1 Vaccines Industry Segmentation

The H1N1 virus, commonly known as swine flu is an infectious disease in humans caused by the swine H1N1 virus, which is characterized by a persistent cough, cold, high fever, red watery eyes, body aches, headache, and general discomfort. H1N1 Vaccines Market is segmented By Product Type, By Route of Administration and Geography.

By Product Type
Inactivated Vaccine
Live Attenuated Vaccine
By Route of Administration
Intradermal Vaccines
Intramuscular Vaccines
Intranasal Vaccines
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

H1N1 Vaccines Market Research FAQs

The H1N1 Vaccines Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)

AstraZeneca Plc, Sanofi (Sanofi Pasteur AG), GlaxoSmithKline Plc, Abbott Laboratories and CSL Limited (Seqirus GmbH) are the major companies operating in the H1N1 Vaccines Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in H1N1 Vaccines Market.

The report covers the H1N1 Vaccines Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the H1N1 Vaccines Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

H1N1 Vaccines Industry Report

Statistics for the 2024 H1N1 Vaccines market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. H1N1 Vaccines analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

H1N1 Vaccines Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

H1N1 Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)